公开(公告)号：EP1444224A2

公开(公告)日：2004-08-11

申请号：EP02748081.3

申请日：2002-08-06

申请人： ELI LILLY AND COMPANY

发明人： BASTIAN, Jolie, Anne ,  FINLEY, Don, Richard ,  HE, John, Xiaoqiang ,  JESUDASON, Cynthia, Darshini ,  RATZ, Andrew, Michael ,  ROCCO, Vincent, Patrick ,  RUEHTER, Gerd,Lilly Research Laboratories Hamburg ,  SALL, Daniel, Jon ,  SCHOTTEN, Theo,Lilly Research Labs. Hamburg ,  SPINAZZE, Patrick, Gianpietro ,  STEVENS, Freddie, Craig ,  TRANKLE, William, George ,  WERNER, John, Arnold

IPC分类号： C07D403/12 ,  A61K31/404 ,  A61P3/04 ,  C07D409/14 ,  C07D401/14 ,  C07D409/12 ,  C07D405/12 ,  C07D209/34 ,  C07D403/14 ,  C07D417/14

CPC分类号： C07D231/12 ,  C07D209/34 ,  C07D233/56 ,  C07D249/08 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D417/14

摘要： The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.